Challenges and opportunities for next-generation sequencing in companion diagnostics

Expert Review of Molecular Diagnostics

Volumn 15, Issue 2, 2015, Pages 193-209

  Lin, Erick ^a   Chien, Jeremy ^b   Ong, Frank S ^a   Fan, Jian Bing ^a  

^a ILLUMINA INC   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

bioinformatics; companion diagnostics; CTC; ctDNA; next generation sequencing; NGS; precision medicine; precision oncology; tumor heterogeneity

Indexed keywords

BISULFITE; DEOXYRIBONUCLEASE I; FORMALDEHYDE;

DIAGNOSTIC TEST; DNA SEQUENCE; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE TECHNOLOGY; HUMAN; KNOWLEDGE BASE; LABORATORY TEST; MOLECULAR DIAGNOSIS; NEOPLASM; NEXT GENERATION SEQUENCING; ONCOGENE; PHENOTYPE; REIMBURSEMENT; REVIEW; TUMOR SUPPRESSOR GENE; WORKFLOW; ECONOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; PERSONALIZED MEDICINE;

GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; KNOWLEDGE BASES; MOLECULAR DIAGNOSTIC TECHNIQUES; SEQUENCE ANALYSIS, DNA;

EID: 84921390202     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.961916     Document Type: Review

References (77)

1. Evans JP. The Human Genome Project at 10 years: a teachable moment. Genet Med 2010;12(8):477
2. Winnick E. Illumina launches two new platforms at JP Morgan Conference; claims $1,000 genome. GenomeWeb 2014. Available from: www.genomeweb.com/.sequencing/illumina-launches-Two-newplatforms-jp-morgan-conference-claims-1000-genome [Last accessed 14 May 2014]
3. Metzker ML. Sequencing technologies- The next generation. Nat Rev Genet 2010;11(1): 31-46
4. Kahn SD. On the future of genomic data. Science 2011;331(6018):728-9
5. Schweitzer EJ. Reconciliation of the cloud computing model with US federal electronic health record regulations. J Am Med Inform Assoc 2012;19(2):161-5
6. Biotechniques. Available from: www. biotechniques.com/BiotechniquesJournal/.2010/February/Sequencings-new-race/.biotechniques-187819.html?pageNum=3
7. Nature. Available from: www.nature.com/.news/nanopore-genome-sequencer-makes-itsdebut-1.10051
8. Ivakhno S, Royce T, Cox AJ, et al. CNAseg- A novel framework for identification of copy number changes in cancer from second-generation sequencing data. Bioinformatics 2010;26(24):3051-8
9. Xie C, Tammi MT. CNV-seq, a new method to detect copy number variation using high-Throughput sequencing. BMC Bioinformatics 2009;10:80
10. Escaramis G, Tornador C, Bassaganyas L, et al. PeSV-Fisher: identification of somatic and non-somatic structural variants using next generation sequencing data. PLoS one 2013;8(5):e63377
11. Chen K, Wallis JW, McLellan MD, et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods 2009; 6(9):677-81
12. Chan KC, Jiang P, Chan CW, et al. Noninvasive detection of cancer-Associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci USA 2013;110(47):18761-8
13. Zhang J, Shi Y, Lalonde E, et al. Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient. BMC Cancer 2013;13:146
14. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31(13):3812-14
15. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7(4):248-9
16. The International HapMap Project. Nature 2003;426(6968):789-96
17. Hamosh A, Scott AF, Amberger J, et al. Online Mendelian Inheritance in Man (OMIM). Hum Mutat 2000;15(1):57-61
18. Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91(2):355-8
19. Sherry ST, Ward M, Sirotkin K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res 1999;9(8): 677-9
20. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 2013;499(7457):214-18
21. Gonzalez-Perez A, Mustonen V, Reva B, et al. Computational approaches to identify functional genetic variants in cancer genomes. Nat Methods 2013;10(8):723-9
22. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012;150(2):251-63
23. Reimand J, Bader GD. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol Syst Biol 2013;9:637
24. ClinVar aggregates information about sequence variation and its relationship to human health. Available from: www.ncbi. nlm.nih.gov/clinvar [Last accessed 14 May 2014]
25. MedGen- Organizes information related to human genetics, such as attributes of conditions with a genetic condition. Available from: www.ncbi.nlm.nih.gov/.medgen [Last accessed 14 May 2014]
26. Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. Nature 2010;464(7291):993-8
27. International cancer genome consortium. Available from: www.icgc.org/.[Last accessed 14 May 2014]
28. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-6
29. FDA-Approved nucleic acid based tests. Available from: www.fda.gov/.MedicalDevices/.ProductsandMedicalProcedures/.InVitroDiagnostics/ucm330711.htm [Last accessed 31 July 2014]
30. FDA-Approved companion diagnostic tests. Available from: www.fda.gov/.MedicalDevices/.ProductsandMedicalProcedures/.InVitroDiagnostics/ucm301431.htm [Last accessed 31 July 2014]
31. Illumina, Amgen ally for diagnostic test- Analyst blog. Available from: www.nasdaq. com/article/illumina-Amgen-Ally-fordiagnostic-Test-Analyst-blog-cm318855 [Last accessed 14 May 2014]
32. PRIME: panitumumab randomized trial in combination with chemotherapy for metastatic colorectal cancer to determine efficacy. Available from: www.clinicaltrials. gov/ct2/results?. term=NCT00364013&Search=Search
33. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34
34. Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012;30(6):593-9
35. Bose P, Park H, Al-Khafaji J, Grant S. Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leuk Res Rep 2013;2(1):18-20
36. Huang D, Kim DW, Kotsakis A, et al. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics 2013; 102(3):157-62
37. Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014;4(1):94-109
38. Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014;4(5):546-53
39. Karnes HE, Duncavage EJ, Bernadt CT. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung. Cancer Cytopathol 2014; 122(2):104-13
40. Chen Y, Shi JX, Pan XF, et al. Identification of candidate genes for lung cancer somatic mutation test kits. Genet Mol Biol 2013;36(3):455-64
41. Wu K, Huang RS, House L, Cho WC. Next-generation sequencing for lung cancer. Future Oncol 2013;9(9):1323-36
42. Tuononen K, Maki-Nevala S, Sarhadi VK, et al. Comparison of targeted next-generation sequencing (NGS) and real-Time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosomes Cancer 2013;52(5):503-11
43. Buttitta F, Felicioni L, Del Grammastro M, et al. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. Clin Cancer Res 2013;19(3):691-8
44. Thomas A, Rajan A, Lopez-Chavez A, et al. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol 2013;24(3):577-85
45. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013;339(6127): 1546-58
46. Singh RR, Patel KP, Routbort MJ, et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 2013; 15(5):607-22
47. Lupo B, Trusolino L. Inhibition of poly (ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim Biophys Acta 2014;1846(1):201-15
48. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011;5(4):387-93
49. Vignot S, Frampton GM, Soria JC, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer J clin oncol 2013;31(17):2167-72
50. Zhang J, Liu J, Sun J, et al. Identifying driver mutations from sequencing data of heterogeneous tumors in the era of personalized genome sequencing. Brief Bioinform 2014;15(2):244-55
51. De Mattos-Arruda L, Bidard FC, Won HH, et al. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. Mol Oncol 2014;8(1):150-8
52. Kosmidou V, Oikonomou E, Vlassi M, et al. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. Hum Mutat 2014;35(3):329-40
53. Ni X, Zhuo M, Su Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci USA 2013; 110(52):21083-8
54. Eswaran J, Cyanam D, Mudvari P, et al. Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep 2012;2:264
55. Weinstein JN, Collisson EA, Mills GB, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013;45(10):1113-20
56. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500
57. Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature Biotechnol 2014;32(5):479-84
58. Dawson SJ, Rosenfeld N, Caldas C. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;369(1):93-4
59. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20(5):548-54
60. Kim SY, Speed TP. Comparing somatic mutation-callers: beyond Venn diagrams. BMC Bioinformatics 2013;14:189
61. Harismendy O, Ng PC, Strausberg RL, et al. Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol 2009;10(3):R32
62. Do H, Wong SQ, Li J, Dobrovic A. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffinembedded DNA by enzymatic depletion of uracil-containing templates. Clin Chem 2013;59(9):1376-83
63. Saunders CJ, Miller NA, Soden SE, et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci Transl Med 2012;4(154): 154ra135
64. Hartzler A, McCarty CA, Rasmussen LV, et al. Stakeholder engagement: a key component of integrating genomic information into electronic health records. Genet Med 2013;15(10):792-801
65. Kho AN, Rasmussen LV, Connolly JJ, et al. Practical challenges in integrating genomic data into the electronic health record. Genet Med 2013;15(10):772-8
66. Hazin R, Brothers KB, Malin BA, et al. Ethical, legal, and social implications of incorporating genomic information into electronic health records. Genet Med 2013; 15(10):810-16
67. Tarczy-Hornoch P, Amendola L, Aronson SJ, et al. A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genet Med 2013; 15(10):824-32
68. Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119(9):1981-7
69. Ellis LM, Hicklin DJ. Resistance to Targeted Therapies: refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res 2009;15(24):7471-8
70. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2012;9(4): 199-207
71. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502(7471):333-9
72. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005; 102(38):13550-5
73. Stoczynska-Fidelus E, Szybka M, Piaskowski S, et al. Limited importance of the dominant-negative effect of TP53 missense mutations. BMC Cancer 2011;11:243
74. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010;2(7):a001107
75. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136(5): 823-37
76. Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007;130(6): 986-8
77. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer cell 2011;19(1):17-30